Cue Health and fitness, best known for its at-house COVID-19 molecular exam, will start its possess digital health and fitness platform, pushing the organization outside of the diagnostics space.
The direct-to-client platform, out there on Nov. 15, will incorporate on-need obtain to medical professionals, guided COVID-19 screening, prescriptions and health practitioner-purchased lab assessments. The digital care offerings are section of a membership program, where shoppers can pay a month-to-month rate for a variety of assessments per year, plus savings on a Cue Reader and added assessments.
“I assume the differentiator below is that we direct with an really highly effective, able diagnostic product or service and the potential to join that take a look at final result to a medical doctor straight away if you would like to,” Clint Sever, Cue Health’s co-founder and main solution officer, explained to MobiHealthNews.
“Or you can come to the platform for any cause and access our suite of medical professionals. They can prescribe for any situation that they need to have to, so you will find a good deal of adaptability developed into the platform that we assume is genuinely significant.”
WHY IT Matters
At the time a additional market technique of healthcare delivery, telehealth and digital-treatment use exploded during the pandemic as individuals and suppliers avoided unwanted in-individual care. Nevertheless telehealth utilization had been declining in June and July, Fair Health’s Month-to-month Telehealth Regional Tracker found utilization grew nationally in August, significantly in the South as the delta variant unfold in the area.
And as far more folks return to journey, team gatherings and gatherings, Sever claimed the supervised COVID-19 tests capabilities offered as section of Cue’s virtual care will also assist differentiate its system.
“A ton of persons, particularly when they journey, want that lab-top quality end result,” Sever stated. “But they are not able to get that lab-excellent final result until they go by a definitely arduous procedure of displaying up at a testing web page and waiting around 24 hours to 48 hours for take a look at outcomes, which may well or may perhaps not get sent to them on time, specially if you’re on a limited timeline.”
THE More substantial Development
Cue has experienced a fast paced 2021. In March, it acquired emergency use authorization from the Foods and Drug Administration for its diagnostic COVID-19 take a look at that does not require a prescription and can be made use of at residence. It had very first obtained an EUA for a level-of-care test in June 2020.
The company scored a significant $235 million in new funding in May perhaps, and announced ideas to go public in early September. By the stop of the month, it had kicked off its $200 million first public featuring.
Sever explained the business is doing work on growing diagnostic offerings that will be compatible with the Cue Reader, like tests for flu, RSV (respiratory syncytial virus), chlamydia, gonorrhea, fertility and pregnancy. But Cue’s very long-term designs go outside of